Evidence map›Paper›PMID 31544132›Full record

ArticleAdvanced therapeutics2018

Decellularized Extracellular Matrix Hydrogels as a Delivery Platform for MicroRNA and Extracellular Vesicle Therapeutics.

Melissa J Hernandez, Roberto Gaetani, Vera M Pieters, Nathan W Ng, Audrey E Chang, Taylor R Martin, Eva van Ingen, Emma A Mol, Joost P G Sluijter, Karen L Christman

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced therapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 52 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Biomaterials science · 2022
    Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Targeted Drug Delivery via the Use of ECM-Mimetic Materials.Frontiers in bioengineering and biotechnology · 2020
    Review
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Melissa J HernandezDepartment of Bioengineering, Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, CA, 92093, USA.
Roberto GaetaniDepartment of Bioengineering, Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, CA, 92093, USA.
Vera M PietersDepartment of Bioengineering, Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, CA, 92093, USA.
Nathan W NgDepartment of Bioengineering, Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, CA, 92093, USA.
Audrey E ChangDepartment of Bioengineering, Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, CA, 92093, USA.
Taylor R MartinDepartment of Bioengineering, Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, CA, 92093, USA.
Eva van IngenDepartment of Bioengineering, Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, CA, 92093, USA.
Emma A MolDepartment of Cardiology, Experimental Cardiology Laboratory, University Medical Center Utrecht, Utrecht, 3584CX, NL.
Joost P G SluijterDepartment of Cardiology, Experimental Cardiology Laboratory, UMC Utrecht Regenerative Medicine Center, University Medical Center Utrecht, Utrecht, 3584CX, NL.
Karen L ChristmanDepartment of Bioengineering, Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, CA, 92093, USA.
Sanford Consortium for Regenerative Medicine · USUniversity of California, San Diego · USUniversity Medical Center Utrecht · NLUniversity of Colorado Denver · US

Funding

Integrative Bioengineering of Heart, Vessels, and BloodT32HL105373 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHIEN, SHU, INTAGLIETTA, MARCOS · 2010 to 2019
$3.6M
Extracellular matrix hydrogels for treating ischemiaR01HL113468 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHRISTMAN, KAREN L · 2012 to 2020
$3.1M
Injectable Skeletal Muscle Matrix in Hypercholesterolemic Mouse Model of Peripheral Artery DiseaseF31HL132584 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HERNANDEZ, MELISSA · 2017 to 2019
$91k
NHLBI NIH HHS F31 HL132584NHLBI NIH HHS R01 HL113468NHLBI NIH HHS T32 HL105373
6 · The paper itself

Abstract

In the last decade, the use of microRNA (miRNA) and extracellular vesicle (EV) therapies has emerged as an alternative approach to mitigate the negative effects of several disease pathologies ranging from cancer to tissue and organ regeneration; however, delivery approaches towards target tissues have not been optimized. To alleviate these challenges, including rapid diffusion upon injection and susceptibility to degradation, porcine-derived decellularized extracellular matrix (ECM) hydrogels are examined as a potential delivery platform for miRNA and EV therapeutics. The incorporation of EVs and miRNA antagonists, including anti-miR and antago-miR, in ECM hydrogels results in a prolonged release as compared to the biologic agents alone. In addition, individual

Indexed as

extracellular matrixextracellular vesicleshydrogelsmicroRNAs

Identifiers

PMID31544132
PMCPMC6753838
OpenAlexW2806250395

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.